Epratuzumab and blinatumomab as therapeutic antibodies for treatment of pediatric acute lymphoblastic leukemia: Current status and future perspectives

Raffaella Franca, Diego Favretto, Marilena Granzotto, Giuliana Decorti, Marco Rabusin, Gabriele Stocco

Research output: Contribution to journalReview article

Abstract

Background: More than 85% of children affected by acute lymphoblastic leukemia (ALL) are successfully treated; however relapse remains a remarkable clinical concern, with 50-60% of relapsing patients facing a fatal outcome. Management of relapsed patients includes standardized intensive risk-Adapted regimens based on conventional drugs, and hematopoietic stem cells transplantation for patients with unfavourable features. Biological drugs, in particular the monoclonal antibody epratuzumab and the bi-functional recombinant single chain peptide blinatumomab, have been recently recognized as novel potential agents to be integrated in salvage ALL therapy to further improve rescue outcome. Methods: A systematic search of peer-reviewed scientific literature and clinical trials in public databases has been carried out. Both clinical and pre-clinical studies have been included to summarize recent evidence on epratuzumab and blinatumomab for salvage ALL therapy. Results: Sixty-Two papers and 25 clinical trials were included. Although not all patients responded properly to these agents, their use in relapsed and refractory pediatric ALL seems promising. Conclusion: Phase 3 studies have recently begun and more consistent results about epratuzumab and blinatumomab safety and efficacy in comparison to conventional therapies are expected in the next years. Epratuzumab seems safe in the dosing scheme proposed in ALL, but its efficacy over the conventional chemotherapy is still questionable. Blinatumomab has shown promising results in high risk cases such as elder adult patients and conclusive studies on pediatric ALL are needed. Patient inter-individual variability to these agents has not been investigated in depth, but this issue needs to be addressed, in particular for blinatumomab.

Original languageEnglish
Pages (from-to)1050-1065
Number of pages16
JournalCurrent Medicinal Chemistry
Volume24
Issue number11
DOIs
Publication statusPublished - Apr 1 2017

Fingerprint

Pediatrics
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Antibodies
Salvaging
Therapeutics
Clinical Trials
Chemotherapy
Literature
Stem cells
Fatal Outcome
Pharmaceutical Preparations
Refractory materials
Hematopoietic Stem Cell Transplantation
Monoclonal Antibodies
blinatumomab
epratuzumab
Peptides
Databases
Safety
Recurrence

Keywords

  • Acute lymphoblastic leukemia
  • Blinatumomab
  • Efficacy
  • Epratuzumab
  • Molecular mechanisms
  • Monoclonal antibodies
  • Pediatrics
  • Toxicity

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Epratuzumab and blinatumomab as therapeutic antibodies for treatment of pediatric acute lymphoblastic leukemia : Current status and future perspectives. / Franca, Raffaella; Favretto, Diego; Granzotto, Marilena; Decorti, Giuliana; Rabusin, Marco; Stocco, Gabriele.

In: Current Medicinal Chemistry, Vol. 24, No. 11, 01.04.2017, p. 1050-1065.

Research output: Contribution to journalReview article

@article{8cb2fb8e434b42658470ca499ef155cd,
title = "Epratuzumab and blinatumomab as therapeutic antibodies for treatment of pediatric acute lymphoblastic leukemia: Current status and future perspectives",
abstract = "Background: More than 85{\%} of children affected by acute lymphoblastic leukemia (ALL) are successfully treated; however relapse remains a remarkable clinical concern, with 50-60{\%} of relapsing patients facing a fatal outcome. Management of relapsed patients includes standardized intensive risk-Adapted regimens based on conventional drugs, and hematopoietic stem cells transplantation for patients with unfavourable features. Biological drugs, in particular the monoclonal antibody epratuzumab and the bi-functional recombinant single chain peptide blinatumomab, have been recently recognized as novel potential agents to be integrated in salvage ALL therapy to further improve rescue outcome. Methods: A systematic search of peer-reviewed scientific literature and clinical trials in public databases has been carried out. Both clinical and pre-clinical studies have been included to summarize recent evidence on epratuzumab and blinatumomab for salvage ALL therapy. Results: Sixty-Two papers and 25 clinical trials were included. Although not all patients responded properly to these agents, their use in relapsed and refractory pediatric ALL seems promising. Conclusion: Phase 3 studies have recently begun and more consistent results about epratuzumab and blinatumomab safety and efficacy in comparison to conventional therapies are expected in the next years. Epratuzumab seems safe in the dosing scheme proposed in ALL, but its efficacy over the conventional chemotherapy is still questionable. Blinatumomab has shown promising results in high risk cases such as elder adult patients and conclusive studies on pediatric ALL are needed. Patient inter-individual variability to these agents has not been investigated in depth, but this issue needs to be addressed, in particular for blinatumomab.",
keywords = "Acute lymphoblastic leukemia, Blinatumomab, Efficacy, Epratuzumab, Molecular mechanisms, Monoclonal antibodies, Pediatrics, Toxicity",
author = "Raffaella Franca and Diego Favretto and Marilena Granzotto and Giuliana Decorti and Marco Rabusin and Gabriele Stocco",
year = "2017",
month = "4",
day = "1",
doi = "10.2174/0929867324666170113105733",
language = "English",
volume = "24",
pages = "1050--1065",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "11",

}

TY - JOUR

T1 - Epratuzumab and blinatumomab as therapeutic antibodies for treatment of pediatric acute lymphoblastic leukemia

T2 - Current status and future perspectives

AU - Franca, Raffaella

AU - Favretto, Diego

AU - Granzotto, Marilena

AU - Decorti, Giuliana

AU - Rabusin, Marco

AU - Stocco, Gabriele

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Background: More than 85% of children affected by acute lymphoblastic leukemia (ALL) are successfully treated; however relapse remains a remarkable clinical concern, with 50-60% of relapsing patients facing a fatal outcome. Management of relapsed patients includes standardized intensive risk-Adapted regimens based on conventional drugs, and hematopoietic stem cells transplantation for patients with unfavourable features. Biological drugs, in particular the monoclonal antibody epratuzumab and the bi-functional recombinant single chain peptide blinatumomab, have been recently recognized as novel potential agents to be integrated in salvage ALL therapy to further improve rescue outcome. Methods: A systematic search of peer-reviewed scientific literature and clinical trials in public databases has been carried out. Both clinical and pre-clinical studies have been included to summarize recent evidence on epratuzumab and blinatumomab for salvage ALL therapy. Results: Sixty-Two papers and 25 clinical trials were included. Although not all patients responded properly to these agents, their use in relapsed and refractory pediatric ALL seems promising. Conclusion: Phase 3 studies have recently begun and more consistent results about epratuzumab and blinatumomab safety and efficacy in comparison to conventional therapies are expected in the next years. Epratuzumab seems safe in the dosing scheme proposed in ALL, but its efficacy over the conventional chemotherapy is still questionable. Blinatumomab has shown promising results in high risk cases such as elder adult patients and conclusive studies on pediatric ALL are needed. Patient inter-individual variability to these agents has not been investigated in depth, but this issue needs to be addressed, in particular for blinatumomab.

AB - Background: More than 85% of children affected by acute lymphoblastic leukemia (ALL) are successfully treated; however relapse remains a remarkable clinical concern, with 50-60% of relapsing patients facing a fatal outcome. Management of relapsed patients includes standardized intensive risk-Adapted regimens based on conventional drugs, and hematopoietic stem cells transplantation for patients with unfavourable features. Biological drugs, in particular the monoclonal antibody epratuzumab and the bi-functional recombinant single chain peptide blinatumomab, have been recently recognized as novel potential agents to be integrated in salvage ALL therapy to further improve rescue outcome. Methods: A systematic search of peer-reviewed scientific literature and clinical trials in public databases has been carried out. Both clinical and pre-clinical studies have been included to summarize recent evidence on epratuzumab and blinatumomab for salvage ALL therapy. Results: Sixty-Two papers and 25 clinical trials were included. Although not all patients responded properly to these agents, their use in relapsed and refractory pediatric ALL seems promising. Conclusion: Phase 3 studies have recently begun and more consistent results about epratuzumab and blinatumomab safety and efficacy in comparison to conventional therapies are expected in the next years. Epratuzumab seems safe in the dosing scheme proposed in ALL, but its efficacy over the conventional chemotherapy is still questionable. Blinatumomab has shown promising results in high risk cases such as elder adult patients and conclusive studies on pediatric ALL are needed. Patient inter-individual variability to these agents has not been investigated in depth, but this issue needs to be addressed, in particular for blinatumomab.

KW - Acute lymphoblastic leukemia

KW - Blinatumomab

KW - Efficacy

KW - Epratuzumab

KW - Molecular mechanisms

KW - Monoclonal antibodies

KW - Pediatrics

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=85022224455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022224455&partnerID=8YFLogxK

U2 - 10.2174/0929867324666170113105733

DO - 10.2174/0929867324666170113105733

M3 - Review article

C2 - 28088906

AN - SCOPUS:85022224455

VL - 24

SP - 1050

EP - 1065

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 11

ER -